436088-75-4

Basic information

• Product Name: 5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID
• Synonyms: 5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID
• CAS NO: 436088-75-4
• Molecular Formula: C10H8N4O3
• Molecular Weight: 232.2
• Mol File: 436088-75-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 493.3°Cat760mmHg
• Flash Point: 252.1°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 1.51E-10mmHg at 25°C
• CAS DataBase Reference: 5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID(436088-75-4)
• EPA Substance Registry System: 5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID(436088-75-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 436088-75-4(Hazardous Substances Data)

Usage

General Description

5-(pyridin-2-ylcarbamoyl)-3H-imidazole-4-carboxylic acid is a chemical compound with the molecular formula C10H9N3O3. It is a derivative of imidazole and is commonly used in the synthesis of pharmaceuticals and agrochemicals. 5-(PYRIDIN-2-YLCARBAMOYL)-3 H-IMIDAZOLE-4-CARBOXYLIC ACID has potential biological activity and is studied for its potential therapeutic applications. It is also used as a building block in organic synthesis and drug discovery. The compound has an imidazole ring system, a carboxylic acid group, and a pyridine ring, making it a versatile and important chemical in various research and industrial applications.

InChI:InChI=1/C10H8N4O3/c15-9(14-6-3-1-2-4-11-6)7-8(10(16)17)13-5-12-7/h1-5H,(H,12,13)(H,16,17)(H,11,14,15)/p-1

Upstream product

• 504-29-0 2-aminopyridine 
• 474013-77-9 5,10-dioxo-5H,10H-diimidazolo[1,5-a:1',5'-d]pyrazine-1,6-dicarboxylic acid diphenyl ester 

Relevant articles and documents

Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction

Though much progress has been made in the inhibition of HIV-1 integrase catalysis, clinical resistance mutations have limited the promise of long-term drug prescription. Consequently, allosteric inhibition of integrase activity has emerged as a promising approach to antiretroviral discovery and development. Specifically, inhibitors of the interaction between HIV-1 integrase and cellular cofactor LEDGF/p75 have been validated to diminish proviral integration in cells and deliver a potent reduction in viral replicative capacity. Here, we have contributed to the development of novel allosteric integrase inhibitors with a high-throughput AlphaScreen-based random screening approach, with which we have identified novel 5-carbonyl-1H-imidazole-4-carboxamides capable of inhibiting the HIV-1 integrase-LEDGF/p75 interaction in vitro. Following a structure-activity relationship analysis of the initial 1H-imidazole-4,5- dicarbonyl core, we optimized the compound's structure through an industrial database search, and we went further to synthesize a selective and non-cytotoxic panel of inhibitors with enhanced potency.